vs

Side-by-side financial comparison of EMPIRE PETROLEUM CORP (EP) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.

EMPIRE PETROLEUM CORP is the larger business by last-quarter revenue ($7.1M vs $3.9M, roughly 1.8× Opus Genetics, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -30.0%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -13.3%).

The Iraq Petroleum Company (IPC), formerly known as the Turkish Petroleum Company (TPC), is an oil company that had a virtual monopoly on all oil exploration and production in Iraq between 1925 and 1961. It was jointly owned by some of the world's largest oil companies and headquartered in London, England.

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

EP vs IRD — Head-to-Head

Bigger by revenue
EP
EP
1.8× larger
EP
$7.1M
$3.9M
IRD
Growing faster (revenue YoY)
IRD
IRD
+19.9% gap
IRD
-10.2%
-30.0%
EP
Faster 2-yr revenue CAGR
IRD
IRD
Annualised
IRD
50.3%
-13.3%
EP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EP
EP
IRD
IRD
Revenue
$7.1M
$3.9M
Net Profit
$-59.0M
Gross Margin
Operating Margin
-834.5%
Net Margin
-835.1%
Revenue YoY
-30.0%
-10.2%
Net Profit YoY
-1306.0%
53.0%
EPS (diluted)
$-1.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EP
EP
IRD
IRD
Q4 25
$7.1M
$3.9M
Q3 25
$9.4M
$3.1M
Q2 25
$8.8M
$2.9M
Q1 25
$9.0M
$4.4M
Q4 24
$10.1M
$4.3M
Q3 24
$11.4M
$3.9M
Q2 24
$12.8M
$1.1M
Q1 24
$9.4M
$1.7M
Net Profit
EP
EP
IRD
IRD
Q4 25
$-59.0M
Q3 25
$-3.8M
$-17.5M
Q2 25
$-5.1M
$-7.4M
Q1 25
$-4.2M
$-8.2M
Q4 24
$-4.2M
Q3 24
$-3.6M
$-7.5M
Q2 24
$-4.4M
$-7.8M
Q1 24
$-4.0M
$-7.1M
Operating Margin
EP
EP
IRD
IRD
Q4 25
-834.5%
Q3 25
-37.8%
-269.9%
Q2 25
-56.0%
-309.0%
Q1 25
-43.9%
-227.2%
Q4 24
-38.9%
Q3 24
-30.0%
-207.1%
Q2 24
-15.0%
-748.9%
Q1 24
-46.8%
-450.5%
Net Margin
EP
EP
IRD
IRD
Q4 25
-835.1%
Q3 25
-40.9%
-566.9%
Q2 25
-57.8%
-257.5%
Q1 25
-46.9%
-187.5%
Q4 24
-41.6%
Q3 24
-32.0%
-194.6%
Q2 24
-34.3%
-698.3%
Q1 24
-42.3%
-415.3%
EPS (diluted)
EP
EP
IRD
IRD
Q4 25
$-1.74
Q3 25
$-0.11
$-0.25
Q2 25
$-0.15
$-0.12
Q1 25
$-0.12
$-0.24
Q4 24
$-0.12
Q3 24
$-0.12
$-0.29
Q2 24
$-0.15
$-0.30
Q1 24
$-0.15
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EP
EP
IRD
IRD
Cash + ST InvestmentsLiquidity on hand
$1.2M
$45.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-4.6M
$15.3M
Total Assets
$65.9M
$50.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EP
EP
IRD
IRD
Q4 25
$1.2M
$45.1M
Q3 25
$4.6M
$30.8M
Q2 25
$2.3M
$32.4M
Q1 25
$1.1M
$41.8M
Q4 24
$2.3M
$30.3M
Q3 24
$3.1M
$36.6M
Q2 24
$9.3M
$41.4M
Q1 24
$3.5M
$47.2M
Total Debt
EP
EP
IRD
IRD
Q4 25
Q3 25
$15.2M
Q2 25
$14.6M
Q1 25
$11.6M
Q4 24
$11.3M
Q3 24
$8.5M
Q2 24
$8.5M
Q1 24
$8.5M
Stockholders' Equity
EP
EP
IRD
IRD
Q4 25
$-4.6M
$15.3M
Q3 25
$53.7M
$6.0M
Q2 25
$54.5M
$17.5M
Q1 25
$59.1M
$5.1M
Q4 24
$62.8M
$6.7M
Q3 24
$56.5M
$34.3M
Q2 24
$58.7M
$40.6M
Q1 24
$31.7M
$46.1M
Total Assets
EP
EP
IRD
IRD
Q4 25
$65.9M
$50.2M
Q3 25
$123.0M
$36.1M
Q2 25
$124.7M
$38.7M
Q1 25
$123.7M
$48.2M
Q4 24
$123.9M
$36.9M
Q3 24
$121.2M
$40.4M
Q2 24
$119.9M
$44.8M
Q1 24
$100.1M
$51.8M
Debt / Equity
EP
EP
IRD
IRD
Q4 25
Q3 25
0.28×
Q2 25
0.27×
Q1 25
0.20×
Q4 24
0.18×
Q3 24
0.15×
Q2 24
0.15×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EP
EP
IRD
IRD
Operating Cash FlowLast quarter
$-2.8M
$-35.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EP
EP
IRD
IRD
Q4 25
$-2.8M
$-35.3M
Q3 25
$330.0K
$-6.2M
Q2 25
$-3.1M
$-10.3M
Q1 25
$1.6M
$-9.0M
Q4 24
$-8.8M
$-25.6M
Q3 24
$12.8M
$-5.1M
Q2 24
$-1.8M
$-7.3M
Q1 24
$3.9M
$-5.7M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons